浅析阿昔替尼药物的中国专利保护现状

Analysis of Patent Protection Situation of Axitinib Drug in China

阿昔替尼是一种酪氨酸激酶抑制剂,用于肾细胞癌(RCC)的二线治疗。本文通过对阿昔替尼在中国的发明专利申请进行检索和统计,分析了其专利申请量总体趋势、地域分布、法律状态和专利申请的技术主题。基于上述关于阿昔替尼的中国专利申请现状的分析,本文以期为国内相关制药企业和研究机构对药物研发和专利保护体系构建提供参考。

Axitinib is a generation tyrosine kinase inhibitor,and it is generally recommended as second-line therapy for advanced RCC.This paper analyzes the general trend of patent applications,regional distribution,legal status and technical themes of patent applications by searching and making statistic of axitinib's invention patent applications in China.Based on the above analysis of the current situation of axitinib patent applications in China,this paper is expected to provide reference for relevant pharmaceutical enterprises and research institutions to research drug and construct patent protection system.